Monoacylglycerol lipase (MAGL) is the pivotal catabolicenzymeresponsible for signal termination in the endocannabinoid system.Inhibition of MAGL offers unique advantages over the direct activationof cannabinoid receptors in treating cancer, metabolic disorders,and inflammatory diseases. This evidence concerns the gene MGLL and metabolic disease.